## Does Shenyi Technology's Angel Round Signal a New Wave of Chinese Consumer BCI Startups?

More than 10 million RMB — roughly $1.4 million USD at current exchange — has landed at Shenzhen-based Shenyi Technology in an angel round led by Guangming Lihe Science City Seed Venture Capital Fund, a vehicle backed by Shenzhen's Angel Mother Fund and Guangming District Guidance Fund. The company, founded in May 2025, is building a dual-track portfolio: non-invasive [closed-loop BCI](https://bciintel.com/glossary/closed-loop) neuromodulation devices targeting clinical neuropsychiatric indications, and consumer-grade [Electroencephalography (EEG)](https://bciintel.com/glossary/eeg) wearables aimed at sleep and emotion management for healthy users.

The capital will fund R&D on core [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) technologies, mass production of consumer products, overseas market expansion, and the clinical verification and registration pathway for medical-grade products — specifically auxiliary diagnosis of depression and neuromodulation devices. The lead investor, Lihe Venture Capital, describes its thesis as "early-stage, small enterprises, hard-core technologies," which puts Shenyi squarely in the category of deep-tech bets rather than app-layer consumer plays.

The company's first medical product is what it claims to be the first domestically developed closed-loop temporal interference (TI) electrical stimulation device industrialized in China — a meaningful technical distinction if the clinical data eventually supports it.

---

## The Temporal Interference Claim Deserves Scrutiny

Temporal interference stimulation is a genuinely differentiated modality. Unlike conventional transcranial direct current stimulation (tDCS) or transcranial magnetic stimulation (TMS), TI uses two high-frequency electrical carrier waves with slightly offset frequencies to produce a low-frequency interference envelope that penetrates to subcortical targets non-invasively. The approach, conceptually validated in rodent models nearly a decade ago, has attracted significant academic and commercial interest precisely because it offers depth selectivity without the heating and discomfort associated with transcranial focused ultrasound.

Shenyi's claim to be building the first Chinese closed-loop TI device for industrialization is specific and verifiable — but it comes from the company's own team, not from independent clinical or regulatory validation. The "closed-loop" element means the stimulation parameters are dynamically adjusted based on real-time multimodal monitoring feedback, rather than delivering a fixed protocol. This architecture is technically more complex and, if it works as described, more clinically compelling than open-loop alternatives. However, no peer-reviewed efficacy data or regulatory filing status (NMPA IDE equivalent) is cited in the source material. Investors and clinicians should treat this as a preclinical/prototype-stage assertion until clinical data emerges.

The company is also pursuing multi-modal combined acoustoelectric stimulation — coordinating focused ultrasound and electrical stimulation — which it describes as a second area of domestic-first industrialization. Again, the claim is from the founding team. The underlying science is legitimate; the industrialization timeline is unverified.

---

## The Dual-Track Strategy: Medical + Consumer

Shenyi's "Serious Medical Care + Consumer Health" dual-track is a structure that Chinese BCI startups have increasingly adopted, and for understandable commercial reasons. The medical registration pathway in China (NMPA) for novel neuromodulation devices is lengthy and capital-intensive. Consumer EEG wearables, by contrast, can reach market faster, generate revenue, and — critically — accumulate real-world EEG datasets at scale.

The company's articulated logic is a data flywheel: consumer product adoption drives EEG data accumulation, which feeds algorithm training and personalized model optimization, which improves both consumer and medical products. This is a coherent thesis, but it carries a well-known tension: consumer EEG signal quality (typically dry electrodes, limited channel counts, high motion artifact) is substantially noisier than clinical-grade EEG. Training diagnostic or neuromodulation algorithms on consumer data and then applying them in medical contexts requires careful domain adaptation — a non-trivial engineering and regulatory challenge.

The [affective BCI](https://bciintel.com/glossary/affective-bci) space — monitoring and modulating emotional states via neural signals — is an area where several global players including [EMOTIV](https://bciintel.com/companies/emotiv) and [Neurable](https://bciintel.com/companies/neurable) have been operating for years. Shenyi will need to differentiate on algorithm performance, hardware ergonomics, and, eventually, clinical-grade evidence for the medical arm.

---

## What This Means for the Chinese BCI Ecosystem

The >10 million RMB angel round is small in absolute terms by Western VC standards, but it is consistent with the early-stage funding dynamics in China's BCI sector, where government-linked seed funds (like the Shenzhen Angel Mother Fund structure here) frequently co-invest alongside strategic private capital to de-risk foundational technology bets. Guangming District in Shenzhen has been actively positioning itself as a hardware and deep-tech corridor, and this investment fits that regional strategy.

For the broader BCI industry trajectory, Shenyi's emergence — less than 18 months after founding — reflects a maturing Chinese BCI startup ecosystem. Where the previous generation of Chinese BCI companies (including [BrainCo](https://bciintel.com/companies/brainco) and others) focused primarily on consumer attention-monitoring applications, the newer cohort is attempting to integrate genuine neuromodulation therapeutics with consumer data infrastructure from day one. This is technically more ambitious and regulatory more complex, but it positions these companies for the clinical validation cycle that will ultimately determine whether non-invasive neuromodulation becomes a reimbursable therapeutic category.

The clinical indications Shenyi is targeting — sleep disorders and depression — are high-prevalence, underserved by existing pharmacological and device-based options, and increasingly the focus of NMPA priority review pathways. If closed-loop TI stimulation can demonstrate objective EEG biomarker-linked efficacy in controlled trials, the regulatory and commercial opportunity is substantial. That is a large "if" at the angel stage.

---

## Key Takeaways

- **Shenyi Technology closed an angel round of more than 10 million RMB**, led by Guangming Lihe Science City Seed Venture Capital Fund, backed by Shenzhen's Angel Mother Fund and Guangming District Guidance Fund.
- **Founded May 2025**, the company targets neuropsychiatric indications (sleep disorders, depression) with non-invasive EEG-based diagnostics and closed-loop neuromodulation.
- **First medical product** is described as China's first domestically developed closed-loop temporal interference (TI) electrical stimulation device for industrialization — a preclinical/prototype-stage claim pending independent clinical or regulatory validation.
- **Dual consumer + medical strategy** uses consumer wearable EEG data to build a training dataset flywheel for clinical algorithm development — a coherent but technically demanding architecture.
- **Multi-modal acoustoelectric stimulation** (combined focused ultrasound + electrical stimulation) is a second technology axis, also described as a domestic-first industrialization effort.
- **Capital allocation**: proceeds targeted at core BCI R&D, consumer product mass production, overseas expansion, and NMPA registration pathway for medical devices.
- **No clinical trial IDs, NMPA filing numbers, or peer-reviewed efficacy data** are available in the source material at this stage.

---

## Frequently Asked Questions

**What is temporal interference stimulation and why does it matter for non-invasive BCI?**
Temporal interference (TI) stimulation uses two high-frequency electrical signals with slightly different frequencies, delivered through scalp electrodes, to generate a low-frequency interference pattern at a targeted depth in the brain. The clinical appeal is non-invasive focality — the ability to stimulate subcortical structures without surgery, unlike conventional tDCS or TMS. Shenyi Technology claims its device is the first closed-loop TI system industrialized in China, meaning stimulation parameters adapt in real time to neural feedback rather than delivering a fixed protocol.

**What is the regulatory pathway for a closed-loop neuromodulation device in China?**
Novel neuromodulation devices in China require NMPA (National Medical Products Administration) approval. The pathway for a Class III medical device — which a closed-loop neurostimulator would likely be classified as — involves clinical trial registration, multi-site controlled trial data, and manufacturing quality system certification. No NMPA filing or trial registration number was disclosed in Shenyi's angel round announcement. The company indicated that capital will be used for "clinical verification and registration transformation," suggesting the formal regulatory pathway has not yet been initiated.

**How does Shenyi Technology's dual-track consumer + medical strategy compare to global competitors?**
Several Western consumer neurotechnology companies, including [EMOTIV](https://bciintel.com/companies/emotiv) and [Neurable](https://bciintel.com/companies/neurable), have built EEG consumer platforms without a parallel medical device arm. Shenyi's model more closely resembles companies like [NeuroPace](https://bciintel.com/companies/neuropace), which built clinical closed-loop expertise, but in reverse — starting with consumer access and feeding data upward to clinical development. The key risk is signal quality: consumer-grade dry EEG data is noisier than clinical EEG, and training diagnostic or therapeutic algorithms on it for medical use requires careful regulatory and technical validation.

**Is the >10 million RMB angel round large enough to reach clinical proof of concept?**
At current RMB/USD exchange rates, >10 million RMB is approximately $1.4 million USD — sufficient for a well-resourced Chinese hardware startup to complete prototype development and early feasibility studies, but not for a full multi-site controlled clinical trial. The government-linked fund structure (Shenzhen Angel Mother Fund participation) suggests follow-on public co-investment is a likely pathway, which is common in China's deep-tech funding ecosystem for early-stage medical device companies.

**What diseases is Shenyi Technology initially targeting?**
The company is focusing on sleep disorders and depression as its primary clinical indications, with a broader platform vision covering neuropsychiatric and brain diseases. Its diagnostic approach uses EEG signal-based auxiliary diagnosis, and its therapeutic approach combines closed-loop TI electrical stimulation with multi-modal acoustoelectric stimulation (focused ultrasound + electrical stimulation). All indications are at the preclinical or early development stage as of the angel round announcement.

---

*This article is based solely on the 36Kr report published August 31, 2026. All claims regarding "first domestically developed" products originate from Shenyi Technology's own team statements, not independent verification. No clinical trial data, peer-reviewed publications, or regulatory filings were cited in the source material. Nothing in this article constitutes medical advice. Results described are from a pre-clinical, early-stage company — not from controlled clinical trials.*